CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
129Xe MRI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03417687
NCT03417687Phase 3Completed
CompareCT.gov

Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Resection Surgery

Polarean, Inc.·interventional·Posted Jan 31, 2018·Updated Jun 28, 2022

In Brief

A Phase 3 clinical trial evaluating 129Xe MRI and 133 Xe scintigraphy for Pulmonary Surgical Procedures. Completed, enrolled 38 participants across 3 sites.

Detailed Summary

This study compares the equivalence of hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung resection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Surgical Procedures
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 31, 2018
Enrollment StartAug 17, 2018
Primary CompletionOct 31, 2019
Study CompletionMar 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.4 years ago

Interventions

129Xe MRIdrug

Evaluation of pulmonary function

133 Xe scintigraphydrug

Evaluation of pulmonary function